Literature DB >> 12013528

Prognostic factors in breast cancer: current and new predictors of metastasis.

D F Hayes1, C Isaacs, V Stearns.   

Abstract

Decisions regarding the use of adjuvant therapy for breast cancer are strongly influenced by the risk of disease recurrence and death. These risks are now determined by examining the currently recognized breast cancer prognostic factors, including clinical stage, axillary nodal status, tumor size and grade, hormone receptor status, and presence of lymphovascular involvement. Newer factors are being evaluated in an attempt to more precisely define disease-related prognosis. This paper provides an overview of issues that need to be considered when analyzing studies of prognostic factors as well as a review of the currently recognized and the newer candidate prognostic factors.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 12013528     DOI： 10.1023/a:1014778713034

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN： 1083-3021            Impact factor:   2.673


  88 in total

1.  Prognostic variables in node-negative and node-positive breast cancer.

Authors:  G Gasparini
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

2.  Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.

Authors:  Anthony J Guidi; Donald A Berry; Gloria Broadwater; Birgit Helmchen; Ira J Bleiweiss; Daniel R Budman; I Craig Henderson; Larry Norton; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Sentinel lymphadenectomy in breast cancer.

Authors:  A E Giuliano; R C Jones; M Brennan; R Statman
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

4.  Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer.

Authors:  Y Utada; M Emi; M Yoshimoto; F Kasumi; F Akiyama; G Sakamoto; S Haga; T Kajiwara; Y Nakamura
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

Review 5.  The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.

Authors:  R W Stephens; N Brünner; F Jänicke; M Schmitt
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

6.  Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study.

Authors:  K W Gilchrist; L Kalish; V E Gould; S Hirschl; J E Imbriglia; W M Levy; A S Patchefsky; D W Penner; J Pickren; J A Roth
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

7.  Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.

Authors:  P P Rosen; S Groshen; D W Kinne; L Norton
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

8.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

9.  Osteopontin expression in a group of lymph node negative breast cancer patients.

Authors:  A B Tuck; F P O'Malley; H Singhal; J F Harris; K S Tonkin; N Kerkvliet; Z Saad; G S Doig; A F Chambers
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

10.  Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.

Authors:  R Seshadri; C S Lee; R Hui; K McCaul; D J Horsfall; R L Sutherland
Journal:  Clin Cancer Res       Date:  1996-07       Impact factor: 12.531
View more
  80 in total

Review 1.  Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Ying Wu; Xiaonan Fu; Xiaoli Zhu; Xuelian He; Chao Zou; Yijie Han; Mingchu Xu; Chengjin Huang; Xin Lu; Yulan Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-29       Impact factor: 4.553

2.  Prognostic role of miR-200c in various malignancies: a systematic review and meta-analysis.

Authors:  Ke-Cheng Zhang; Hong-Qing Xi; Jian-Xin Cui; Wei-Song Shen; Ji-Yang Li; Bo Wei; Lin Chen
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Low expression of let-7 predicts poor prognosis in patients with multiple cancers: a meta-analysis.

Authors:  Yang Xia; Yi Zhu; Xiaoying Zhou; Yijiang Chen
Journal:  Tumour Biol       Date:  2014-04-23

4.  Clinical implications of activated leukocyte cell adhesion molecule expression in breast cancer.

Authors:  Daxun Piao; Tao Jiang; Gavin Liu; Baosheng Wang; Jin Xu; Anlong Zhu
Journal:  Mol Biol Rep       Date:  2011-06-14       Impact factor: 2.316

5.  Biofunctional characteristics of in situ and invasive breast carcinoma.

Authors:  Sara Bravaccini; Anna Maria Granato; Laura Medri; Flavia Foca; Fabio Falcini; Wainer Zoli; Monica Ricci; Giuseppe Lanzanova; Nestory Masalu; Luigi Serra; Federico Buggi; Secondo Folli; Rosella Silvestrini; Dino Amadori
Journal:  Cell Oncol (Dordr)       Date:  2013-06-27       Impact factor: 6.730

6.  Monocyte chemotactic protein-1 expression as a prognosic biomarker in patients with solid tumor: a meta analysis.

Authors:  Hong Wang; Qiongwen Zhang; Hongyu Kong; Yunhui Zeng; Meiqin Hao; Ting Yu; Jing Peng; Zhao Xu; Jingquan Chen; Huashan Shi
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 7.  p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Authors:  A Alkarain; R Jordan; J Slingerland
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

8.  EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Authors:  Heather M Moore; Maria E Gonzalez; Kathy A Toy; Ashley Cimino-Mathews; Pedram Argani; Celina G Kleer
Journal:  Breast Cancer Res Treat       Date:  2013-03-29       Impact factor: 4.872

9.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

10.  Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course.

Authors:  Michaelann Liss; Nandhini Sreedhar; Albert Keshgegian; Guido Sauter; Michael R Chernick; George C Prendergast; U Margaretha Wallon
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.